{"id":"6ae0e26a220c","type":"article","url":"https://hartvaat.nl/2025/12/01/gelijktijdige-griep-en-rsv-vaccinatie-bij-hoogrisico-hartfalenpatienten/","title":"Gelijktijdige griep- en RSV-vaccinatie bij hoogrisico hartfalenpatiënten","title_en":"Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.15432","source_url":"https://doi.org/10.1002/ehf2.15432","authors":["Jan Biegus","Leszek Szenborn","Michał Tkaczyszyn","Robert Zymlinski","Gad Cotter","Michał Zakliczynski","Krzysztof Reczuch","Mateusz Guzik","Szymon Urban","Marta Rosiek-Biegus","Berenika Jankowiak","Gracjan Iwanek","Marta Wleklik","Marat Fudim","Piotr Ponikowski"],"significance":5,"published":"2025-12-01","source_date":"2025-12-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/"],"congress":"","summary_en":"A prospective randomised study evaluated simultaneous influenza and RSV vaccination in high-risk heart failure patients. The co-vaccination strategy was safe and effective, potentially improving vaccine uptake in this vulnerable population.","created":"2026-07-03T10:32:01Z","updated":"2026-07-03T13:31:00Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie onderzocht de haalbaarheid en veiligheid van gelijktijdige griep- en RSV-vaccinatie bij hartfalenpatiënten. De co-vaccinatie was veilig en effectief, wat de vaccinatiegraad kan verhogen.","abstract_original":"BACKGROUND: There is a scarcity of prospective data on the impact of available vaccinations against respiratory viruses on hard clinical endpoints in patients with heart failure (HF). AIMS: We investigated whether, in the population of high-risk HF patients, simultaneous vaccination against influenza and respiratory syncytial virus (RSV) improves outcomes during the subsequent infection season. METHODS: We conducted a prospective, randomized, single-centre, open-label study in which patients with high-risk HF were randomized 1:1 to simultaneous influenza and RSV vaccination or standard of care (SOC). The primary composite endpoint comprised all-cause death, HF hospitalization (HFH) or clinical signs/symptoms of infection within a 6 month follow-up period (regular structured telephone interview). Secondary endpoints were components of the composite primary endpoint. RESULTS: Two hundred twenty patients were randomized. During the follow-up period, the primary endpoint occurred in 59% of patients in the vaccination group versus 75% in the SOC group [hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.48-0.92, P = 0.01]. Regarding the secondary endpoint analyses, during 6 month follow-up, 3% in the vaccination group died compared with 5% of patients in the SOC arm (HR 0.50, 95% CI 0.12 1.99, P = 0.32), and 18% versus 16% of study participants were hospitalized for HF in the two study arms, respectively (HR 0.86, 95% CI 0.45-1.62, P = 0.64). Infection occurred in 53% of vaccinated patients compared with 68% in SOC (HR 0.68, 95% CI 0.48-0.96, P = 0.03). CONCLUSIONS: In the population of high-risk HF, simultaneous vaccination against influenza and RSV reduced the incidence of the primary outcome. The effect was driven by a significant reduction in infections."}